27.3 C
Vientiane
Saturday, June 28, 2025
spot_img
Home Blog Page 752

JULIEN’S AUCTIONS PRESENTS BOLD LUXURY: THE LIMELIGHT EDIT

Featuring Iconic Fashion from Marilyn Monroe, Elizabeth Taylor, Cher, Victoria Beckham, Amy Winehouse, Hermes, Chanel, Giambatista Valli & More

A Landmark Sale of Fashion and Hollywood Iconography

Live at The Peninsula Beverly Hills | March 27, 2025
Online Registration & Bidding Opens: February 27, 2025

BEVERLY HILLS, Calif., Feb. 27, 2025 /PRNewswire/ — Julien’s Auctions, the industry leader in high-profile luxury and celebrity memorabilia sales, proudly announces Bold Luxury: The Limelight Edit, an exclusive auction featuring some of the most sought-after designer fashion and celebrity-worn pieces. Taking place on March 27, 2025, at The Peninsula Beverly Hills, this premier event will bring together collectors, investors, and fashion aficionados to bid on a meticulously curated selection of rare and historic pieces.

A Defining Moment for Luxury and Celebrity Collectibles

From Marilyn Monroe to Elizabeth Taylor, Cher, and Britney Spears, this extraordinary collection represents the pinnacle of Hollywood glamour and haute couture. Each piece embodies a cultural legacy, offering a rare opportunity to own tangible history.

“Bold Luxury is a celebration of fashion’s most iconic moments. These one-of-a-kind artifacts transcend mere clothing—they represent the intersection of style, storytelling, and investment,” said Martin Nolan, Co-Founder and Executive Director of Julien’s Auctions.

Auction Highlights

Elizabeth Taylor:
  • 14K Gold and Diamond Evening Purse
  • Art Deco Emerald and Diamond Brooch, Circa 1935
Marilyn Monroe:
  • 1961 The Misfits Cowboy Boots from the Personal Collection of Dee & Tommy Hilfiger.
  • 1954 Jeans from “River of No Return” from the Personal Collection of Dee & Tommy Hilfiger.
Cher & Britney Spears:
  • Cher’s 2002 Stage-Worn If I Could Turn Back Time Costume by Bob Mackie
  • Britney Spears’ 2001 Bob Mackie Jubilee Burlesque Ensemble
Luxury Fashion Pieces:
  • Hermès Limited Edition Framboise Matte Alligator Birkin
  • Paco Rabanne 1999 Spring Haute Couture Dress

Luxury as an Investment

As the luxury collectibles market grows, designer fashion and celebrity memorabilia gain value. Julien’s Bold Luxury series captures this shift, attracting both seasoned and new collectors.

How to Bid

  • Online Registration & Bidding Open: February 27, 2025
  • Live Auction: March 27, 2025, The Peninsula Beverly Hills
  • Bid Online: www.juliensauctions.com

This must-attend event redefines bold luxury, offering a front-row seat to history.

For more information about Julien’s Auctions or any additional questions, please contact:

Media Contact
Jenelle Hamilton PR
Jenelle Hamilton
jenelle@jenellehamlton.com
+1 646.421.9139

Video – https://www.youtube.com/watch?v=zhzV06CED_8

 

Open Compute Project Foundation and JEDEC Drive Open Silicon Innovation

New Chiplet Design Kits Enable New Silicon Supply Chains

AUSTIN, Texas, Feb. 27, 2025 /PRNewswire/ — Today, the Open Compute Project Foundation (OCP), the nonprofit organization bringing hyperscale innovations to all, and JEDEC Solid State Technology Association, the global leader in the development of standards for the microelectronics industry, announce the availability of new Chiplet Design Kits for use with today’s EDA tools covering Assembly, Substrate, Material and Test developed in collaboration within the OCP Open Chiplet Economy Project. Leveraging the alliance between OCP and JEDEC, these design kits are now part of the Global World Wide Standard JEDEC JEP30: Part Model Guidelines.


The release of the Assembly, Substrate, Material, and Test Design Kits build on earlier joint efforts between the OCP and JEDEC integrating OCP Chiplet Data Extensible Markup Language (CDXML) specification into  JEDEC JEP30: Part Model Guidelines, enabling Chiplet builders to provide electronically a standardized Chiplet part description to their customers, paving the way for automating System-in-Package (SiP) design and build using Chiplets.

“The new design kits, developed through collaboration between OCP and JEDEC, promote innovation in SiP design by fostering collaboration and openness, ensuring broad accessibility, and supporting rapid adoption across the semiconductor industry. These kits promote openness, streamline design workflows, and reduce manual interventions, thereby significantly improving design efficiency, scalability, and innovation,” said James Wong, Palo Alto Electron, David Ratchkov, Thrace Systems and Michael Durkan, Chair of the JEDEC JEP30 Task Group. The integration of the design kits with the rest of the PartModel enforces consistent terminology across the Chiplets and the rules that support the development of SiP, eliminating the need for re-mapping within the design tools.

  • The Assembly and Substrate Design Kits enables efficient integration of heterogeneous Chiplets by defining standardized rule formats and tolerances for key design elements such as geometries, layers, interconnects and assembly processes.
  • The Material Design Kit provides a comprehensive framework for defining, evaluating, and validating the material properties and design parameters required for SiP. It focuses on critical elements such as substrates, interposers, redistribution layers and 3D integration technologies. The kit emphasizes the importance of material properties, such as dielectric constants, thermal conductivity and mechanical strength, to optimize performance, reliability and cost-efficiency.
  • The Test Design Kit, which is being standardized within JEDEC, enables the planning, design and manufacturing of SiP, with a particular emphasis on testability, enabling standardization of the testing process for Chiplet integration, with a focus on standard definitions for test elements, test flow requirements and definition of test-only elements, and support for test in advanced manufacturing.

“Chiplets have rapidly become the efficient and cost-effective way to develop chips at leading-edge nodes, and have been used successfully to improve SiP performance with cost efficiencies at scale, because the entire chip development cycle is managed in-house at large companies. To provide an open environment where designers drop known-good third-party sourced Chiplets into their designs requires the development of an open marketplace. Recently the OCP took the next step in establishing an Open Chiplet Economy with the opening of the OCP Chiplet Marketplace.  Moving forward the OCP intends to become the front door to an open Chiplet marketplace, making available a catalogue of standalone Chiplets, new standardizations, tools and best practices that would be required for a truly open economy,” said Cliff Grossner, Ph.D., Chief Innovation Officer at the Open Compute Project Foundation.

The schemas included in the Assembly, Materials and Test design kits as integrated into the JEDEC JEP:30 Part Model Guidelines have been designed to scale to a very large number of Chiplet interconnection points while keeping the schema size manageable. Security is also of utmost importance and all schema files are digitally signed to ensure no corruption, when shared between chiplet buyer to seller.

“There are still many opportunities to create additional standardization efforts bringing together JEDEC’s strength in setting global standards for the microelectronics industry with OCP’s expertise in specifying system level devices seeding emerging technologies and markets. JEDEC is delighted with this next step in the collaboration with OCP moving the market forward,” said John Kelly, President, JEDEC. 

“The next inflection point for the silicon supply chain is open, with innovation driven by a collaborative community, just as we have seen with the computing platforms of the cloud computing era. Developing an open stand-alone Chiplet silicon supply chain will require a rethink of this supply chain. Many design decisions made by Chiplet designers will impact packaging, test and verification, and the software stack, which will all be done by separate organizations, unlike today, where most silicon design is done in-house using proprietary processes,” said Tom Hackenberg, Principal Analyst in Computing & Software at Yole Group.

About the Open Compute Project Foundation
The Open Compute Project (OCP) is a global collaborative Community of hyperscale data center operators, telecom, colocation providers and enterprise IT users, working with the product and solution vendor ecosystem to develop open innovations deployable from the cloud to the edge. The OCP Foundation is responsible for fostering and serving the OCP Community to meet the market and shape the future, taking hyperscale-led innovations to everyone. Meeting the market is accomplished through addressing challenging market obstacles with open specifications, designs and emerging market programs that showcase OCP-recognized IT equipment and data center facility best practices. Shaping the future includes investing in strategic initiatives and programs that prepare the IT ecosystem for major technology changes, such as AI & ML, optics, advanced cooling techniques, composable memory and silicon. OCP Community-developed open innovations strive to benefit all, optimized through the lens of impact, efficiency, scale and sustainability. Learn more at www.opencompute.org.

About JEDEC
JEDEC is the global leader in the development of standards for the microelectronics industry. Thousands of volunteers representing over 350 member companies work together in more than 100 JEDEC committees and task groups to meet the needs of every segment of the industry, manufacturers and consumers alike. The publications and standards generated by JEDEC committees are accepted throughout the world.  All JEDEC standards are available for download from the JEDEC website. For more information, visit www.jedec.org.

Media Contacts
Dirk Van Slyke
Open Compute Project Foundation
dirkv@opencompute.org  
Mobile: +1 303-999-7398
(Central Time Zone/CST/Austin, TX)

Emily Desjardins
JEDEC
703-907-7560
emilyd@jedec.org
(Eastern Time Zone/EST/Arlington, VA)

 

Mainstream Renewable Power Appoints Morten Henriksen as CEO

FORNEBU, Norway, Feb. 27, 2025 /PRNewswire/ — The Board of Mainstream Renewable Power (“Mainstream”), the pureplay global wind and solar company majority-owned by Aker Horizons ASA, is pleased to announce the appointment of Morten Henriksen as Group CEO, effective April 1, 2025. Henriksen comes from the position of CEO of Gassnova, the Norwegian state enterprise for carbon capture and storage. His previous experience spans executive management roles in the energy industry in Norway and internationally for companies including Arendals Fossekompani and Statkraft, in addition to multiple board positions.

Current CEO Mary Quaney will continue to support Mainstream and the transition in a Senior Advisor capacity before stepping down in the second half of 2025 to pursue other interests.

The appointment comes as the Company implements its updated strategy, continuing to deliver significant cost base reduction targets and sharpening its focus on three core growth markets where it sees the greatest potential for value creation – South Africa, Australia, and the Philippines.

In order to reduce costs and leverage the resources of its majority shareholder Aker Horizons, Mainstream is relocating its headquarters from Dublin to Oslo in the first half of 2025. This is in line with its plan to reduce its cost base by approximately 65% by 2026, relative to 2023 levels.

Mainstream’s Chairman, Kristian Røkke, said: “We would like to express our gratitude to Mary for her leadership over the last five years. She has guided Mainstream’s global team with focus, resilience and integrity, navigating a period of industry-wide transformation.”

He continued: “As we enter a new phase, Morten brings extensive experience and deep sector expertise to position Mainstream for growth. His leadership will be instrumental in executing the Company’s strategy and driving Mainstream’s growth in the global energy market.”

Commenting on his appointment, Morten Henriksen said: “Mainstream is well positioned for the opportunities ahead. I am very excited about implementing our vision to build a lean and focused renewable energy company, leading in our core markets and creating value through strong project execution, a lean cost base and capital efficiency.”

For further information, please contact:
Jonas Gamre, Investor Relations, tel: +47 97 11 82 92,
email: jonas.gamre@akerhorizons.com
Mats Ektvedt, Media, tel: +47 41 42 33 28,
email: mats.ektvedt@corporatecommunications.no

About Aker Horizons

Aker Horizons develops green energy and green industry to accelerate the transition to Net Zero. The company is active in renewable energy, carbon capture and sustainable industrial assets. As part of the Aker group, Aker Horizons applies industrial, technological and capital markets expertise with a planet-positive purpose to drive decarbonization globally. Aker Horizons is listed on the Oslo Stock Exchange and headquartered in Fornebu, Norway. Across its portfolio, the company is present on five continents. www.akerhorizons.com

About Mainstream Renewable Power

Mainstream Renewable Power is a leading pure-play renewable energy company with wind and solar assets across Europe, Latin America, Africa, and Asia-Pacific. Mainstream is one of the most successful developers of gigawatt-scale renewables platforms, across onshore wind, offshore wind, and solar power generation. The company has successfully delivered 6.6 GW of wind and solar generation assets to financial close-ready and has a global project portfolio of 22.7 GW. www.mainstreamrp.com

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/aker-horizons/r/mainstream-renewable-power-appoints-morten-henriksen-as-ceo,c4111882

 

Ubie and Nucleus Genomics Partner to Enhance Access to Genetic Testing and Drive Early Screening for Improved Health Outcomes

  • Genetic testing can be critical to ensuring the early diagnosis and proper treatment of serious disease for patients of all ages
  • The partnership combines Ubie’s AI-driven symptom identification and high rates of patient engagement with Nucleus Genomics’ cutting-edge complete DNA sequencing
  • Engaging with patients while they are looking for answers for their health issues makes it possible to identify potential genetic disorders early in the healthcare journey

NEW YORK, Feb. 27, 2025 /PRNewswire/ — Ubie, a global healthcare AI platform that guides patients to better interactions with providers and life sciences, and Nucleus Genomics, the next-generation genetic testing and analysis company, today announced the outcomes of a partnership to improve access to genetic screening and early disease detection. The collaboration leverages Ubie’s AI-powered Symptom Checker and Nucleus Genomics sophisticated genetic testing capabilities to address care gaps and underdiagnosis in healthcare by connecting individuals who may have undiagnosed conditions with advanced genetic screening options early in the care journey.

A genetic disorder is a disease caused by a change in the DNA sequence. These mutations can be inherited or occur spontaneously leading to a wide range of health issues depending on which gene is affected. Genetic testing can help guide decisions about medical care by effectively diagnosing the disease and ensuring proper treatment. With Ubie’s ability to reach patients before their diagnosis, genetic testing can give patients a head start on identifying mutations and guidance on the right course of action, which can include lifestyle changes, preventative measures and earlier treatment with personalized medicine.

A growing leader in the diagnostics space, Nucleus Genomics expands access to genetic screening and testing beyond what patients may be able to get from their regular healthcare providers. The company is using its partnership with Ubie to reach more and better motivated patients, and expand and diversify its user base.

“Nucleus Genomics is committed to driving innovation in genetic testing in order to get patients the answers they need at the right point in their care journey,” said Halle Marchese, Director of Marketing & Communications at Nucleus Genomics. “Initial results from our partnership with Ubie have shown outstanding engagement, connecting us with motivated consumers actively seeking answers about their health to get the insights and genetic counseling they need to make informed and impactful decisions about their care.”

The partnership focuses on several key areas, including the early detection of genetic predispositions to various health conditions, improved access to genetic screening for underserved populations, enhanced patient education about genetic factors in common and rare diseases, and personalized health insights based on both symptoms and genetic markers.

Leveraging Ubie, Nucleus reached more than 277,000 patients in the first four months. Outcomes highlighted the value of ultra-targeted messaging, as target users clicked-through nearly 10x higher than healthcare benchmarks. By matching patients with disease-specific genetic education, Ubie also increased engagement more than 30% relative to baseline.

Furthermore, Ubie diversified Nucleus’s representation, reaching  patients ranging from 18 to 90 years of age, with 87% over 50, and 82% of users identifying as female – a focus for Nucleus Genomics. Engagement for rare diseases and progressive conditions saw even higher engagement, outperforming Ubie’s average by approximately 200%, further supporting the recent launch of Nucleus Genomics rare disease panel screening.

“This partnership represents a significant step forward in democratizing access to genetic testing. This will empower patients, who are already actively searching for answers, to take control of their care,” said Kota Kubo, Co-Founder and CEO of Ubie. “This partnership is an example of how connecting disparate pieces of healthcare and providing patients with the insights they need can have an impact on appropriate care and outcomes.”

Previously, most consumer genetic tests used microarray testing, which looks at less than 0.1% of DNA sequencing, meaning that important health insights can be missed. Nucleus Genomics analyzes 100% of a patient’s DNA, with 30x high-depth whole-genome sequencing coverage, providing a more complete picture and insights on genetic risk for 900+ conditions.

Nucleus Genomics is a medical provider delivering whole-genome sequencing, cancer screening, heart screening and neurology screening. The company’s recent $14 million Series A funding round highlights its effectiveness and impact in the market, with the company looking to dramatically expand its genetic risk assessments and add features to help users plan healthy families.

About Nucleus Genomics

Nucleus is redefining next-generation genetic testing and analysis. By combining polygenic scores with traditional rare variant DNA analysis, the company provides comprehensive assessments of genetic disposition across a myriad of diseases and traits. Nucleus’ mission is to empower people to take agency over their health so no one dies from preventable disease — that’s why the company is building a platform based on cutting-edge science, where everyone has their genome at their fingertips, complete clarity on their risks, and are empowered by personalized health measures. Learn more at mynucleus.com.

About Ubie

Founded in 2017, Ubie empowers individuals and healthcare professionals with the tools they need for better care. Leveraging cutting-edge disease prediction AI, Ubie guides 10+ million patients every month to seek appropriate medical attention through its free online Symptom Checker and equips 1,500+ provider organizations with clinical tools that streamline workflows and support better diagnoses and health outcomes. Trained on medical data, Ubie’s marketing solutions power advanced targeting capabilities and high-performing digital campaigns for 70% of the world’s top life science companies.

Learn more about our vision and work at https://ubiehealth.com/company or try our free Symptom Checker at https://ubiehealth.com/.

EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements

PROVIDENCE, R.I., Feb. 27, 2025 /PRNewswire/ — EpiVax, Inc. proudly announces the appointment of Guilhem Richard as Chief Technology Officer. Dr. Richard joined EpiVax’s immunoinformatics team in 2014 and spearheaded the development of a new computational platform for developing personalized, neoantigen-based cancer vaccines: Ancer®. He subsequently oversaw translational work of this technology at EpiVax’s subsidiary company, EpiVax Therapeutics, Inc., from 2019 to 2024. Dr. Richard is now leading innovation efforts at EpiVax and is overseeing the development of new and enhanced computational tools for immunogenicity assessment. He holds a M.Eng. in Bioinformatics and Modeling from the National Institute of Applied Sciences (INSA) of Lyon, France, and a Ph.D. in Bioinformatics from Boston University.

The promotion of Dr. Richard coincides with several key advancements in EpiVax’s technology and offerings. EpiVax reports significant updates, leveraging advanced artificial intelligence (AI) and machine learning (ML) techniques, to several of the core immunoinformatic assets included in the company’s ISPRI platform. The updates will further enhance the leading platform’s immunogenicity risk assessment features for biologic therapeutics. The new models have enabled EpiVax researchers to refine prediction of tolerated epitopes, improving both precision and recall of its JanusMatrix model by 50%. In addition, new immunogenicity models predicting the rate of anti-drug antibodies (ADA) against monoclonal therapeutics have led to a 6-fold increase in the correlation between predicted and observed values over existing approaches, while significantly reducing the rate of false negative (low predicted immunogenicity / high observed immunogenicity) by 85%. These updated tools will become available on EpiVax’s ISPRI platform, accessible on a SaaS and fee-for-service basis in coming months, enhancing accuracy of results of a key assessment step in the development process for global biotech and pharma clients and collaborators.

In addition, EpiVax has filed a new Model Master File (MMF) for its PANDA® In Silico Model to the FDA, supporting regulatory filing of Abbreviated New Drug Applications (ANDA) of generic peptide drugs. EpiVax’s PANDA® MMF provides detailed descriptions of its models and methodologies for assessing the immunogenicity of peptide drugs and their impurities and can now be referenced as a Drug Master File (DMF) in FDA ANDA fillings. The accessibility of EpiVax’s PANDA® MMF represents an important step in streamlining the preparation and review of ANDAs, enabling sponsors to simplify their regulatory package and FDA reviewers to access in-depth background and validation information regarding  EpiVax’s immunogenicity models.

EpiVax remains committed to driving innovation with several planned improvements for the ISPRI platform upcoming, including a new version of EpiMatrix® to further enhance the toolkit’s predictive capabilities. Additionally, guided analysis features and an updated user interface for ISPRI will provide a more user-friendly experience, empowering our partners in strengthening their pipelines.

About EpiVax
EpiVax is a leader in preclinical immunogenicity assessment and sequence optimization for peptide therapeutics, biologic therapeutics, and vaccines. EpiVax partners with a global roster of companies, agencies, and academics to accelerate immunogenicity risk assessment, immune modulation, and rapid vaccine design.

Press Contact
Sarah Moniz
Director, Business Development
EpiVax
smoniz@epivax.com

Lunit Achieves Milestone at ECR 2025: 13 Oral Presentations Among 15 AI Studies, Demonstrating Unmatched Clinical Impact

  • Lunit to present 15 studies, with an unprecedented 13 accepted as oral presentations, marking a significant milestone in AI-powered radiology research
  • Key studies demonstrate AI’s capability to replace one radiologist in double reading, detect subclinical breast cancer years in advance, and maintain robust performance despite image quality challenges

SEOUL, South Korea, Feb. 27, 2025 /PRNewswire/ — Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a landmark achievement at the European Congress of Radiology (ECR) 2025, taking place in Vienna, Austria, from February 26 to March 2. With 15 research abstracts accepted and 13 designated as oral presentations, this year’s participation marks Lunit’s largest and most influential presence at ECR to date. 

The high acceptance rate underscores Lunit’s growing leadership in AI-driven radiology, with its research recognized as highly relevant to the future of cancer screening and detection. Among the featured studies, two highlight groundbreaking findings that further solidify Lunit INSIGHT MMG as a clinically proven tool in mammography interpretation and workflow optimization. 

Replacing One Radiologist with AI for Independent Double Reading in Mammographic Screening

Presented by Marie Burns Bergan from BreastScreen Norway, this study evaluates the impact of replacing one radiologist with Lunit INSIGHT MMG in a large-scale double-reading mammography screening program. The research analyzed over 1 million mammography screenings, testing various AI thresholds to assess AI’s role in maintaining detection accuracy while reducing radiologists’ workload. 

Key findings include:

  • AI successfully detected up to 79.9% of screen-detected cancers at a 10% positivity threshold.
  • At a 5% threshold, AI maintained 75.5% cancer detection while also identifying 5.7% of interval cancers, which are often missed by traditional screening.
  • AI integration reduced radiologists’ reading workload by 50%, optimizing resources without significantly compromising detection accuracy. 

This study highlights Lunit INSIGHT MMG’s ability to serve as a reliable second reader, supporting AI’s role in improving efficiency and alleviating radiologist shortages in high-volume screening programs. 

Using Artificial Intelligence to Detect Subclinical Breast Cancer

Led by Jonas Gjesvik from BreastScreen Norway, this study investigates whether Lunit INSIGHT MMG can identify subtle cancer risk indicators years before a formal diagnosis. The analysis involved 116,000 women who participated in a long-term mammography screening program, assessing AI’s ability to assign risk scores and track disease progression. 

Key findings include: 

  • AI assigned higher risk scores to breasts that later developed cancer, even up to six years before diagnosis.
  • AI scores for screen-detected breast cancers increased significantly from 19.2 to 82.7 across consecutive screenings, indicating early disease detection. 
  • For interval cancers, AI identified elevated risk earlier than traditional methods, paving the way for more personalized screening strategies. 

The study underscores AI’s potential to enhance breast cancer risk prediction, shifting screening protocols toward a personalized, risk-based model. This research aligns with ongoing work leveraging Volpara’s breast density analysis, further strengthening the Lunit-Volpara ecosystem in AI-driven breast cancer risk assessment. 

In addition to these highlighted studies, Lunit will present a total of 15 research abstracts, further demonstrating AI’s role in enhancing diagnostic accuracy, optimizing workflow, and supporting radiologists worldwide. 

“This year’s ECR is a landmark moment for Lunit, with our highest-ever number of oral presentations, underscoring our leadership in AI-powered radiology research,” said Brandon Suh, CEO of Lunit. “From replacing a radiologist in double-reading settings to predicting breast cancer years in advance, these findings reinforce AI’s potential to transform breast cancer detection, optimize radiology workflows, and ultimately improve patient outcomes.” 

Join Lunit at booth AI-19 in the EXPO X1 hall to explore the latest advancements in AI-powered cancer detection and discuss potential collaborations in the evolving field of AI-driven radiology. 

Presentations featuring Lunit INSIGHT at ECR 2025

About Lunit

Founded in 2013, Lunit (KRX:328130.KQ) is a medical AI company on a mission to conquer cancer. Lunit harnesses AI-powered medical image analytics and biomarker analysis to ensure accurate diagnosis and optimal treatment for each cancer patient. The FDA-cleared Lunit INSIGHT suite for cancer screening serves over 4,800 hospitals and medical institutions across 55+ countries. Lunit clinical studies have been published in top journals, including the Journal of Clinical Oncology and the Lancet Digital Health, and presented at global conferences such as the ASCO and RSNA. Headquartered in Seoul, South Korea, with a network of offices worldwide, Lunit leads the global fight against cancer. Discover more at lunit.io.

Visionary Aggressively Expands Its High – Tech Landscape, Empowering New Momentum for Market Value Growth

TORONTO, Feb. 27, 2025 /PRNewswire/ — Since May 8, 2024, Visionary Holdings (referred to as “Visionary”, NASDAQ stock code: GV) has released the significant news of its industrial upgrading and strategic expansion globally. It has achieved remarkable and substantial results in various fields. With decisive transformation decisions and efficient implementation strategies, Visionary has successfully overcome the development bottlenecks of traditional education and traditional real estate, smoothly advanced into the new arenas of AI – education and technology – based real estate. Simultaneously, it has been steadily expanding into emerging industrial sectors such as high – tech and fintech. Gradually, it has established a diversified multinational group framework integrating four core businesses: technology, education, finance, and real estate, demonstrating strong comprehensive competitiveness and broad development potential in the global market.

Recently, Visionary has reached a strategically – significant cooperation agreement in the new – energy vehicle industry with Pegasus International Holding Limited and So, Sumi Susanna. This cooperation is highly consistent with the current development trend of the new – energy industry, sending positive signals from multiple dimensions and injecting strong impetus into boosting investors’ confidence and strengthening market – value management.

cooperation agreement
cooperation agreement

Capital Operation and Listing Plan: Targeting Value Growth

In terms of capital operation, Pegasus International Holding Limited will be incorporated into Visionary’s new – energy vehicle industry project. The two parties plan to facilitate the successful listing of the project on the NASDAQ Main Board in the United States within 6 to 12 months. This efficient listing plan not only showcases Visionary’s high confidence in the value of its own project and its robust capital – operation capabilities but also opens a clear value – growth channel for investors. Additionally, the long – term plan to assist Pegasus International in listing on the Main Board of the Hong Kong Stock Exchange within the next 3 to 5 years further broadens the path of capital appreciation, laying a solid foundation for the continuous increase of the company’s market value and instilling confidence in investors regarding the company’s long – term development.

Large – Scale Orders and Product Strength: Bolstering Performance Support

Pegasus International has placed an order with Visionary for the purchase of 12,000 new – energy vehicles (Hong Kong taxi version) at a unit price of HK$145,800. This substantial order is undoubtedly a powerful testament to the quality of Visionary’s products and its market competitiveness. In Hong Kong, a mature market with a high penetration rate of new – energy vehicles, securing an order of such scale fully indicates that Visionary’s products have gained high market recognition. The stable and substantial order revenue will directly translate into a powerful driving force for the company’s performance growth, providing solid performance support for market – value enhancement and enabling investors to clearly perceive the company’s profitability and development potential in the market.

Diversified Market Expansion: Unveiling a New Chapter of Growth

The Hong Kong and Southeast Asian markets are emerging hotspots for the global development of new – energy vehicles. In the Hong Kong region, due to the government’s tax – reduction, subsidy policies, and the continuous improvement of charging infrastructure, the new – energy vehicle market is booming. Electric vehicles account for a relatively high proportion in the number of first – time private – car registrations. In the Southeast Asian region, governments of various countries have actively introduced incentive policies. For example, Thailand, Malaysia, Indonesia, and Vietnam have all provided subsidies and tariff exemptions, attracting numerous new – energy vehicle manufacturers to compete for market share.

Visionary, together with its partners, is jointly developing the new – energy light – truck market in Hong Kong and expanding the battery – swapping/charging service business for new – energy vehicles in Hong Kong and Southeast Asia, accurately grasping the market development trend. The diversified market layout can not only effectively diversify market risks but also bring new profit – growth points to the company, significantly enhancing the company’s comprehensive competitiveness and market share in the new – energy industry. It demonstrates to investors the company’s broad development prospects and strong risk – resistance capabilities.

This cooperation represents a major strategic breakthrough for Visionary in the new – energy vehicle field. From capital operation, product – market performance to business expansion, it comprehensively showcases the company’s strong strength and forward – looking strategic vision. It is believed that through the joint efforts of both parties, Visionary will progress steadily in the new – energy vehicle market, continuously create substantial value for investors, and achieve a two – way increase in the company’s market value and investors’ confidence.

For more information, please contact:

Visionary Holdings Inc.

Investor Relations Department

Email: ir@farvision.ca 

IBM Completes Acquisition of HashiCorp, Creates Comprehensive, End-to-End Hybrid Cloud Platform

HashiCorp’s capabilities drive significant synergies across multiple strategic growth areas for IBM, including Red Hat, watsonx, data security, IT automation and Consulting

ARMONK, N.Y., Feb. 27, 2025 /PRNewswire/ — IBM (NYSE: IBM) today announced it has completed its acquisition of HashiCorp, whose products automate and secure the infrastructure that underpins hybrid cloud applications and generative AI. Together the companies’ capabilities will help clients accelerate innovation, strengthen security, and get more value from the cloud.

HashiCorp, an IBM Company.
HashiCorp, an IBM Company.

Today nearly 75% of enterprises are using hybrid cloud1, including public clouds from hyperscalers and on-prem data centers, which can enable true innovation with a consistent approach to delivering and managing that infrastructure at scale. Enterprises are looking for ways to more efficiently manage and modernize cloud infrastructure and security tasks from initial planning and design, to ongoing maintenance. By 2028, it is projected that generative AI will lead to the creation of 1 billion new cloud-native applications.2 Supporting this scale requires infrastructure automation far beyond the capacity of the workforce alone.

“Organizations globally are looking to deploy modern, hybrid cloud-ready apps, which require automated cloud infrastructure at significant scale,” said Rob Thomas, Senior Vice President, IBM Software and Chief Commercial Officer. “With this acquisition, IBM is committed to continuing to invest in and grow the HashiCorp capabilities, and together, with HashiCorp’s leading technology and extensive developer community, IBM’s global reach and R&D resources, our aim is to infuse HashiCorp technology in every data center.”

“HashiCorp has been helping the world’s largest enterprises succeed in hybrid and multi-cloud environments for over a decade. We’ve seen the cloud grow from its origins, and have participated first-hand in the change it has brought to the industry,” said Dave McJannet, CEO, HashiCorp. “With IBM’s history, global scale, and customer relationships, HashiCorp can now expand our reach to help our community of customers, practitioners, and partners automate, secure, and optimize their cloud infrastructure, providing an end-to-end platform for hybrid environments.”

“HashiCorp has been a pioneer in cloud infrastructure since the earliest days of public cloud. We’ve built a portfolio of products to help customers embrace a cloud native approach to Infrastructure and Security Lifecycle Management that has been embraced by hundreds of thousands of organizations around the world,” said Armon Dadgar, CTO and Co-founder of HashiCorp. “I’m excited for HashiCorp to join the IBM family, where there is clear alignment on the vision of enabling hybrid infrastructure for the world’s biggest enterprises. Together, we can continue to invest deeply in R&D innovation and enable the next generation of applications to be built and scaled.”

Product detail and availability

  • HashiCorp’s capabilities enable enterprises to use automation to deliver lifecycle management for infrastructure and security, providing a system of record for the critical workflows needed for hybrid and multi-cloud environments. HashiCorp Terraform is a leader for infrastructure provisioning in these environments. HashiCorp’s offerings help clients take a highly interoperable approach to multi-cloud management, and complement IBM’s commitment to industry collaboration (including deep and expanding partnerships with hyperscale cloud service providers), developer and open source communities for hybrid cloud and AI innovation.
  • Its Terraform and Vault offerings, along with the broader HashiCorp product portfolio, are available now from IBM’s automation software portfolio.
  • HashiCorp will drive significant synergies for IBM, including across multiple strategic growth areas like Red Hat, watsonx, data security, IT automation and Consulting. For example, Terraform and the Red Hat Ansible Automation Platform provide a powerful combination, with Terraform automating the foundational infrastructure creation across multiple cloud providers, and Ansible automating application configurations and middleware deployments on top of that infrastructure. 
  • In addition, HashiCorp Vault combined with Red Hat OpenShift provide robust secrets management and security capabilities across hybrid cloud environments, and Terraform can enable the building and deployment of IBM Z applications in hybrid cloud environments.

Builds on IBM’s Portfolio of AI-driven IT Automation Capabilities

The HashiCorp acquisition continues IBM’s broad investments in automation software to help organizations optimize their IT spending and lower costs. This includes AI-powered software for  application management insights across clients’ portfolios to identify, predict, and suggest fixes for problems; software for full IT stack observability and to optimize application performance at the lowest cost; application resource management tools that efficiently scale operations and reduce cloud expense; financial management solutions that drive real-time insight into IT spending decisions across the enterprise; and software to integrate thousands of applications and data across hybrid cloud environments.

The closing of IBM’s acquisition of HashiCorp includes all of the issued and outstanding common shares of HashiCorp for $35 per share in cash, representing an enterprise value of $6.4 billion.

For more information about today’s news, please visit https://www.ibm.com/products/hashicorp and visit https://www.hashicorp.com/en/blog/hashicorp-officially-joins-the-ibm-family to read more from HashiCorp co-founder and CTO Armon Dadgar.

Sources:

About IBM:
IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Thousands of government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service. Visit www.ibm.com for more information. 

CONTACT: 
IBM
Hanna Scalzo
smigala@us.ibm.com 

IBM Corporation logo.
IBM Corporation logo.